EBS
Price
$6.51
Change
+$0.08 (+1.24%)
Updated
May 22, 04:59 PM (EDT)
Capitalization
120.07M
82 days until earnings call
PBH
Price
$84.93
Change
+$0.51 (+0.60%)
Updated
May 22, 04:59 PM (EDT)
Capitalization
3.6B
70 days until earnings call
Interact to see
Advertisement

EBS vs PBH

Header iconEBS vs PBH Comparison
Open Charts EBS vs PBHBanner chart's image
Emergent Biosolutions
Price$6.51
Change+$0.08 (+1.24%)
Volume$21.55K
Capitalization120.07M
Prestige Consumer Healthcare
Price$84.93
Change+$0.51 (+0.60%)
Volume$2.78K
Capitalization3.6B
EBS vs PBH Comparison Chart
Loading...
EBS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PBH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EBS vs. PBH commentary
May 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EBS is a Hold and PBH is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
May 23, 2025
Stock price -- (EBS: $6.43 vs. PBH: $84.42)
Brand notoriety: EBS and PBH are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: EBS: 119% vs. PBH: 113%
Market capitalization -- EBS: $120.07M vs. PBH: $3.6B
EBS [@Pharmaceuticals: Other] is valued at $120.07M. PBH’s [@Pharmaceuticals: Other] market capitalization is $3.6B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.7B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EBS’s FA Score shows that 1 FA rating(s) are green whilePBH’s FA Score has 2 green FA rating(s).

  • EBS’s FA Score: 1 green, 4 red.
  • PBH’s FA Score: 2 green, 3 red.
According to our system of comparison, PBH is a better buy in the long-term than EBS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EBS’s TA Score shows that 5 TA indicator(s) are bullish while PBH’s TA Score has 6 bullish TA indicator(s).

  • EBS’s TA Score: 5 bullish, 4 bearish.
  • PBH’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, PBH is a better buy in the short-term than EBS.

Price Growth

EBS (@Pharmaceuticals: Other) experienced а +14.01% price change this week, while PBH (@Pharmaceuticals: Other) price change was -1.15% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.10%. For the same industry, the average monthly price growth was +10.36%, and the average quarterly price growth was +30.06%.

Reported Earning Dates

EBS is expected to report earnings on Aug 12, 2025.

PBH is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (-0.10% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PBH($3.6B) has a higher market cap than EBS($120M). EBS has higher P/E ratio than PBH: EBS (17.73) vs PBH (14.90). PBH YTD gains are higher at: 8.106 vs. EBS (-32.741). PBH has higher annual earnings (EBITDA): 10.8M vs. EBS (-518.2M). EBS has more cash in the bank: 112M vs. PBH (63.6M). EBS has less debt than PBH: EBS (860M) vs PBH (1.21B). PBH has higher revenues than EBS: PBH (1.13B) vs EBS (1.02B).
EBSPBHEBS / PBH
Capitalization120M3.6B3%
EBITDA-518.2M10.8M-4,798%
Gain YTD-32.7418.106-404%
P/E Ratio17.7314.90119%
Revenue1.02B1.13B90%
Total Cash112M63.6M176%
Total Debt860M1.21B71%
FUNDAMENTALS RATINGS
EBS vs PBH: Fundamental Ratings
EBS
PBH
OUTLOOK RATING
1..100
1510
VALUATION
overvalued / fair valued / undervalued
1..100
56
Fair valued
83
Overvalued
PROFIT vs RISK RATING
1..100
1008
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4145
P/E GROWTH RATING
1..100
1022
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EBS's Valuation (56) in the Biotechnology industry is in the same range as PBH (83) in the Pharmaceuticals Other industry. This means that EBS’s stock grew similarly to PBH’s over the last 12 months.

PBH's Profit vs Risk Rating (8) in the Pharmaceuticals Other industry is significantly better than the same rating for EBS (100) in the Biotechnology industry. This means that PBH’s stock grew significantly faster than EBS’s over the last 12 months.

PBH's SMR Rating (100) in the Pharmaceuticals Other industry is in the same range as EBS (100) in the Biotechnology industry. This means that PBH’s stock grew similarly to EBS’s over the last 12 months.

EBS's Price Growth Rating (41) in the Biotechnology industry is in the same range as PBH (45) in the Pharmaceuticals Other industry. This means that EBS’s stock grew similarly to PBH’s over the last 12 months.

EBS's P/E Growth Rating (10) in the Biotechnology industry is in the same range as PBH (22) in the Pharmaceuticals Other industry. This means that EBS’s stock grew similarly to PBH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EBSPBH
RSI
ODDS (%)
Bearish Trend 2 days ago
88%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
57%
Momentum
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
64%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
63%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
54%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
56%
Advances
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 7 days ago
59%
Declines
ODDS (%)
Bearish Trend 8 days ago
89%
Bearish Trend 2 days ago
52%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
52%
Aroon
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
54%
View a ticker or compare two or three
Interact to see
Advertisement
EBS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PBH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GCSSX24.05N/A
N/A
Goldman Sachs Small Cap Eq Insghts Svc
GMEYX12.77N/A
N/A
GuideStone Funds Impact Equity Instl
NICSX93.92N/A
N/A
Nicholas
JSVPX23.22N/A
N/A
JPMorgan Small Cap Value R3
BALCX34.56-0.39
-1.12%
American Funds American Balanced C

EBS and

Correlation & Price change

A.I.dvisor indicates that over the last year, EBS has been loosely correlated with AMRX. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if EBS jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EBS
1D Price
Change %
EBS100%
-7.35%
AMRX - EBS
35%
Loosely correlated
-2.02%
HROW - EBS
31%
Poorly correlated
-4.77%
SIGA - EBS
31%
Poorly correlated
-1.13%
VTRS - EBS
29%
Poorly correlated
-4.50%
ZOMDF - EBS
29%
Poorly correlated
+1.23%
More

PBH and

Correlation & Price change

A.I.dvisor indicates that over the last year, PBH has been loosely correlated with PAHC. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if PBH jumps, then PAHC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PBH
1D Price
Change %
PBH100%
-3.59%
PAHC - PBH
48%
Loosely correlated
-3.49%
VTRS - PBH
38%
Loosely correlated
-4.50%
AMRX - PBH
32%
Poorly correlated
-2.02%
ZTS - PBH
32%
Poorly correlated
-1.35%
IRWD - PBH
32%
Poorly correlated
-9.72%
More